NeoGenomics launches PanTracer LBx liquid biopsy CGP test for advanced solid tumors (ir.neogenomics.com)

• Blood-based CGP test for advanced solid tumors
• Analyzes ctDNA for over 500 genes
• Seven-day turnaround time
• Addressable liquid biopsy market estimated at $3–5 billion

"NeoGenomics announced the launch of PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test for advanced solid tumors. The ctDNA test covers over 500 genes, offers a seven-day turnaround, and is intended for therapy selection, trial matching, and monitoring when tissue is limited or unavailable. The launch expands NeoGenomics' pan-solid tumor CGP portfolio into the growing liquid biopsy market estimated at $3–5 billion."